SEPTEMBER 9, 2021
Biophytis today announces the appointment of Rob van Maanen MD MBA as Chief Medical Officer, member of the Executive Committee.
AUGUST 16, 2021
Biophytis receives favorable recommendation from Data Monitoring Committee (DMC) based on safety analysis of Sarconeos (BIO101) to continue patients recruitment in the COVA study in COVID-19
AUGUST 13, 2021
Biophytis announces today that it has performed the obligations imposed on it by (i) the judgment of the Commercial Court of Paris (Tribunal de commerce de Paris) of March 16, 2021 and (ii) the judgment of July 16, 2021 of the Enforcement Judge of the Judicial Court of Paris (Juge de l’exécution du Tribunal Judiciaire…
AUGUST 12, 2021
Interview by Didier Testot Founder to watch on LA BOURSE ET LA VIE TV
AUGUST 2, 2021
Top line results of SARA-INT Phase 2 study with Sarconeos (BIO101) in Sarcopenia
JULY 19, 2021
Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Negma Group Ltd by the Execution Judge from the Paris Court of Justice
JULY 12, 2021
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
April 19, 2021
Interview of Stanislas Veillet, CEO of Biophytis on La Bourse ou la Vide.com (in French)
FEBRUARY 26, 2021
Biophytis Reports 2020 Full Year Results
FEBRUARY 17, 2021
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium